Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Elimination of Mother-to-Infant Transmission of Hepatitis B Virus: 35 Years of Experience

  • Lu, Fang-Ting (Department of Pediatrics, Changhua Christian Hospital) ;
  • Ni, Yen-Hsuan (Department of Pediatrics, National Taiwan University Children's Hospital, College of Medicine, National Taiwan University)
  • Received : 2019.12.28
  • Accepted : 2020.05.23
  • Published : 2020.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

Chronic hepatitis B viral (HBV) infection remains a major health threat, especially in high-prevalence areas. Most infants infected by mother-to-infant HBV transmission become chronic carriers. In Taiwan, many important preventive interventions have been implemented to block the perinatal transmission of HBV in the past 35 years. The first nationwide universal HBV vaccination program was launched in Taiwan in July 1984. The three-dose HBV vaccine completion rate reached 98.1% in 2018. The prevalence of Hepatitis B surface antigen (HBsAg) decreased from 9.8% in pre-vaccinated period in 1984 to 0.5% in the vaccinated cohort in 2014. The incidence of hepatocellular carcinoma in children aged 6-9 years significantly declined from 0.52 to 0.13 per 100,000 children born before and after 1984, respectively. Furthermore, we have performed a maternal HBV screening program during pregnancy since 1984, with the screening rate peaked at 93% in 2012. The HBsAg- and HBeAg-seropositive rate in pregnant women declined from 13.4% and 6.4% in 1984-1985 to 5.9% and 1.0% in 2016, respectively. To closely control perinatal HBV infection, we have administered hepatitis B immunoglobulin immediately after birth and checked the serum level of HBsAg and anti-HBs in high-risk babies born to HBsAg-seropositive mothers, irrespective of their HBeAg status, since July 2019. We have also adopted short-term antiviral treatments such as tenofovir 300 mg daily in the third trimester for highly viremic mothers and reduced the perinatal infection rates from 10.7 to 1.5%. Through all these efforts, we expect to meet the global goal of eliminating HBV infection by 2030.

Keywords

References

  1. World Health Organization. Global hepatitis report, 2017. Geneva: World Health Organization, 2017.
  2. Smith S, Harmanci H, Hutin Y, Hess S, Bulterys M, Peck R, et al. Global progress on the elimination of viral hepatitis as a major public health threat: an analysis of WHO Member State responses 2017. JHEP Rep 2019;1:81-9. https://doi.org/10.1016/j.jhepr.2019.04.002
  3. Hutin YJ, Bulterys M, Hirnschall GO. How far are we from viral hepatitis elimination service coverage targets? J Int AIDS Soc 2018;21(Suppl 2):e25050. https://doi.org/10.1002/jia2.25050
  4. Chang MH. Hepatitis B vaccination: disease and cancer prevention-a Taiwanese experience. Clin Liver Dis 2010;14:521-30. https://doi.org/10.1016/j.cld.2010.05.010
  5. Hsu SC, Chang MH, Ni YH, Hsu HY, Lee CY. Horizontal transmission of hepatitis B virus in children. J Pediatr Gastroenterol Nutr 1993;16:66-9. https://doi.org/10.1097/00005176-199301000-00012
  6. Ni YH, Chen DS. Hepatitis B vaccination in children: the Taiwan experience. Pathol Biol (Paris) 2010;58:296-300. https://doi.org/10.1016/j.patbio.2009.11.002
  7. Chien YC, Jan CF, Kuo HS, Chen CJ. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006;28:126-35. https://doi.org/10.1093/epirev/mxj010
  8. Nayagam S, Thursz M. Strategies for global elimination of chronic HBV infection: 2019 update. Curr Hepatol Rep 2019;18:300-9. https://doi.org/10.1007/s11901-019-00478-w
  9. Su WJ, Chen SF, Yang CH, Chuang PH, Chang HF, Chang MH. The impact of universal infant hepatitis B immunization on reducing the hepatitis B carrier rate in pregnant women. J Infect Dis 2019;220:1118-26. https://doi.org/10.1093/infdis/jiy706
  10. Lin CC, Hsieh HS, Huang YJ, Huang YL, Ku MK, Hung HC. Hepatitis B virus infection among pregnant women in Taiwan: comparison between women born in Taiwan and other southeast countries. BMC Public Health 2008;8:49. https://doi.org/10.1186/1471-2458-8-49
  11. Chen HL, Lin LH, Hu FC, Lee JT, Lin WT, Yang YJ, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology 2012;142:773-81.e2. https://doi.org/10.1053/j.gastro.2011.12.035
  12. Chen SC, Toy M, Yeh JM, Wang JD, Resch S. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment. Pediatrics 2013;131:e1135-43. https://doi.org/10.1542/peds.2012-1262
  13. Hsu HY, Chang MH, Chen DS, Lee CY, Sung JL. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol 1986;18:301-7. https://doi.org/10.1002/jmv.1890180402
  14. Tsen YJ, Chang MH, Hsu HY, Lee CY, Sung JL, Chen DS. Seroprevalence of hepatitis B virus infection in children in Taipei, 1989: five years after a mass hepatitis B vaccination program. J Med Virol 1991;34:96-9. https://doi.org/10.1002/jmv.1890340205
  15. Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in taiwan. JAMA 1996;276:906-8. https://doi.org/10.1001/jama.1996.03540110060032
  16. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001;135:796-800. https://doi.org/10.7326/0003-4819-135-9-200111060-00009
  17. Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 2007;132:1287-93. https://doi.org/10.1053/j.gastro.2007.02.055
  18. Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 2012;57:730-5. https://doi.org/10.1016/j.jhep.2012.05.021
  19. Ni YH, Chang MH, Jan CF, Hsu HY, Chen HL, Wu JF, et al. Continuing decrease in hepatitis B virus infection 30 years after initiation of infant vaccination program in Taiwan. Clin Gastroenterol Hepatol 2016;14:1324-30. https://doi.org/10.1016/j.cgh.2016.04.030
  20. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. Gevana: World Health Organization, 2016.
  21. Lu CY, Ni YH, Chiang BL, Chen PJ, Chang MH, Chang LY, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008;197:1419-26. https://doi.org/10.1086/587695
  22. Chang MH, Lee CY, Chen DS, Hsu HC, Lai MY. Fulminant hepatitis in children in Taiwan: the important role of hepatitis B virus. J Pediatr 1987;111:34-9. https://doi.org/10.1016/S0022-3476(87)80338-4
  23. Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001;139:349-52. https://doi.org/10.1067/mpd.2001.116277
  24. Chen HL, Chang CJ, Kong MS, Huang FC, Lee HC, Lin CC, et al. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology 2004;39:58-63. https://doi.org/10.1002/hep.20006
  25. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 2013;310:974-6. https://doi.org/10.1001/jama.2013.276701
  26. Chang MH, Chen DS, Hsu HC, Hsu HY, Lee CY. Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. Cancer 1989;64:2377-80. https://doi.org/10.1002/1097-0142(19891201)64:11<2377::AID-CNCR2820641130>3.0.CO;2-8
  27. Chang MH, You SL, Chen CJ, Liu CJ, Lai MW, Wu TC, et al. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology 2016;151:472-80.e1. https://doi.org/10.1053/j.gastro.2016.05.048
  28. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9. https://doi.org/10.1056/NEJM199706263362602
  29. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009;101:1348-55. https://doi.org/10.1093/jnci/djp288
  30. Wen WH, Chang MH, Zhao LL, Ni YH, Hsu HY, Wu JF, et al. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol 2013;59:24-30. https://doi.org/10.1016/j.jhep.2013.02.015
  31. Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH. Hepatitis B surface antigenemia at birth: a long-term follow-up study. J Pediatr 1998;133:374-7. https://doi.org/10.1016/S0022-3476(98)70272-0
  32. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67:1560-99. https://doi.org/10.1002/hep.29800
  33. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-98. https://doi.org/10.1016/j.jhep.2017.03.021
  34. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1-98.
  35. Chen HL, Wen WH, Chang MH. Management of pregnant women and children: focusing on preventing mother-to-infant transmission. J Infect Dis 2017;216(suppl_8):S785-91. https://doi.org/10.1093/infdis/jix429
  36. Song J, Yang F, Wang S, Tikande S, Deng Y, Tang W, et al. Efficacy and safety of antiviral treatment on blocking the mother-to-child transmission of hepatitis B virus: a meta-analysis. J Viral Hepat 2019;26:397-406.
  37. Chen HL, Lee CN, Chang CH, Ni YH, Shyu MK, Chen SM, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology 2015;62:375-86. https://doi.org/10.1002/hep.27837
  38. Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med 2016;374:2324-34. https://doi.org/10.1056/NEJMoa1508660
  39. Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med 2018;378:911-23. https://doi.org/10.1056/NEJMoa1708131
  40. Wen WH, Huang CW, Chie WC, Yeung CY, Zhao LL, Lin WT, et al. Quantitative maternal hepatitis B surface antigen predicts maternally transmitted hepatitis B virus infection. Hepatology 2016;64:1451-61. https://doi.org/10.1002/hep.28589
  41. Chang KC, Chang MH, Lee CN, Chang CH, Wu JF, Ni YH, et al. Decreased neonatal hepatitis B virus (HBV) viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers. Aliment Pharmacol Ther 2019;50:306-16. https://doi.org/10.1111/apt.15321

Cited by

  1. Human hepatitis viruses-associated cutaneous and systemic vasculitis vol.27, pp.1, 2020, https://doi.org/10.3748/wjg.v27.i1.19
  2. Association of HLA-DPA1, HLA-DPB1, and HLA-DQB1 Alleles With the Long-Term and Booster Immune Responses of Young Adults Vaccinated Against the Hepatitis B Virus as Neonates vol.12, 2021, https://doi.org/10.3389/fimmu.2021.710414